secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2026-06-24T20:47:58+00:00
Accession:  0001193125-26-281200
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences adopts bylaw amendments, authorizes reverse stock split
------------------------------------------------------------------------------

- Board approved amended employment agreements for CEO & CFO: 2x salary+bonus severance on change in control, 18-mo COBRA, 3-year term.
- Stockholders authorized reverse stock split up to 1:250 within one year, allowing Board to fix ratio without further approval.
- Bylaws updated: universal proxy rule compliance, formal 'Cause' definition for officers/directors, removal only for cause due to classified board.
- Elected Jennifer Carver as Class A director to serve until 2029 annual meeting; ratified Baker Tilly as auditor for FY2026.
- Emergency succession framework added for CEO/CFO vacancies: CFO assumes CEO duties, CEO assumes CFO duties pending Board action.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000119312526281200/0001193125-26-281200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000119312526281200/revb-20260624.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-281200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer